An Open Label Randomized, Multi-Centre Exploratory Phase II Study to Evaluate the Efficacy and Safety of the Combination of Panitumumab With FOLFOX 4 Chemotherapy or Panitumumab With FOLFIRI Chemotherapy in Subjects With Wild- Type KRAS Colorectal Cancer and Liver-Only Metastases

Trial Profile

An Open Label Randomized, Multi-Centre Exploratory Phase II Study to Evaluate the Efficacy and Safety of the Combination of Panitumumab With FOLFOX 4 Chemotherapy or Panitumumab With FOLFIRI Chemotherapy in Subjects With Wild- Type KRAS Colorectal Cancer and Liver-Only Metastases

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Feb 2018

At a glance

  • Drugs Panitumumab (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms PLANET
  • Most Recent Events

    • 01 Feb 2018 Results of pooled data from PRIME (NCT00364013), PEAK (NCT00819780) and PLANET (NCT00885885) assessing impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer receiving treatment with panitumumab, were published in the Journal of Cancer Research and Clinical Oncology.
    • 12 Sep 2017 Results of pooled data from two trial (MACRO-2 and PLANET) assessing the impact of tumor location on the efficacy of first line anti-EGFR monoclonal antibody plus chemotherapy in patients with metastatic colorectal cancer, were presented at the 42nd European Society for Medical Oncology Congress.
    • 17 Jun 2017 Results published in the European Journal of Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top